Breaking News, Trials & Filings

Merck’s KEYTRUDA Shows Improvement Bladder Cancer

Demonstrates statistically significant and clinically meaningful improvement in one of the study’s primary endpoints of disease-free survival.

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

Merck announced results from the Phase 3 AMBASSADOR (A031501)/KEYNOTE-123 trial evaluating KEYTRUDA for the adjuvant treatment of high-risk patients with localized muscle-invasive urothelial carcinoma (MIUC) and locally advanced resectable urothelial carcinoma.    At the trial’s first pre-specified interim analysis, after a median follow-up of 22.3 months, KEYTRUDA demonstrated a statistically significant and clinically meaningful improvement in one of the study’s dual primary endpoints of dis...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters